Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl. 1: 13–17. 10. Pham PA, Bartlett JG. Moxifloxacin [online]. Available from http://www.hopkinsguides.com/hopkins/ub/view/Johns_Hopkins_ABX_Guide/540355/all/Moxifloxacin selleck chemicals [Accessed 2012 Jan 28]. 11. Balfour JA, Wiseman LR. Moxifloxacin. Drugs 1999; 57 (3): 363–73.PubMedCrossRef 12. Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile
of moxifloxacin. Clin Infect Dis 2001; 32 Suppl. 1: S51–63.PubMedCrossRef 13. Culley CM, Lacy MK, Klutman N, et al. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm 2001; 58 (5): 379–88.PubMed 14. Talan DA. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001; 32 Suppl. 1: S64–71.PubMedCrossRef 15. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: Selleck ABT263 focus on respiratory infections. Drugs 2002; 62 (1): 13–59.PubMedCrossRef 16. Blondeau JM. The role of fluoroquinolones in skin and skin structure infections.
Am J Clin Dermatol 2002; 3 (1): 37–46.PubMedCrossRef 17. Muijsers RB, Jarvis B. Moxifloxacin in uncomplicated skin and skin structure infections. Drugs 2002; 62 (6): 967–73.PubMedCrossRef 18. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26 (7): 940–50.PubMedCrossRef 19. Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 2004; 64 (20): 2347–77.PubMedCrossRef 20. Llor C, LCL161 solubility dmso Naberan K, Cots JM, et al. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care. Int J Clin Pract 2004; 58 (10): 937–44.PubMedCrossRef
21. Van Bambeke F, Michot JM, Van Eldere J, et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005; Dipeptidyl peptidase 11 (4): 256–80.PubMedCrossRef 22. Sethi S. Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41 Suppl. 2: S177–85.PubMedCrossRef 23. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005; 118 Suppl. 7A: 29S–38S.PubMedCrossRef 24. Ferrara AM. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection 2005; 33 (3): 106–14.PubMedCrossRef 25. Haggerty CL, Ness RB. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin Infect Dis 2007; 44 (7): 953–60.PubMedCrossRef 26. Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis 2007; 2 (3): 191–204.PubMed 27. Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone.